| abstract |
Disclosed herein is a wearable drug delivery device including a container filled at least npartially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin nType 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, nor a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may ninclude a needle and an insertion mechanism configured to insert the needle into a patient. A fluid npathway connector may define a sterile fluid flowpath between the container and the insertion nmechanism. Optionally, a cannula initially disposed about the needle may be included. The ncannula may be retained in the patient at an injection site created by the needle after the needle is nwithdrawn from the patient. Methods of assembly and operation are also provided. nFigure. 115AnWO 2017/177094 PCT/US2017/026524 n9610 96200 15 n96202/ nW) A n96206 FIG 11 5A n96210 n96101 W n96101 n-96101 G n96202 2i n96 150 n96102--/ 96101 A nFIG 115b |